VAC4EU (Vaccine monitoring Collaboration for Europe) elected its Executive Board during its second General Assembly held 14th October. Eva Molero, CEO of Teamit Institute was appointed new member of the Board. Miriam Sturkenboom, head of the Department of Data Science and Biostatistics at the University Medical Center Utrecht (Netherlands); Rosa Gini, Head of the Pharmacoepidemiology Unit of the Agenzia regionale di sanità della Toscana (Italy) and Patrick Mahy, Professor at the Haute Ecole ‘Léonard de Vinci’ Bruxelles (Belgium) are the other Executive Board members, serving as President, Vice-president and Treasurer respectively.
VAC4EU is a multi-stakeholder international association with a study network to run studies and an open community for scientific debate. VAC4EU provides real world evidence on vaccine coverage, benefits and risks in Europe to support public health and decision making. The overall mission of VAC4EU is to enable, coordinate and accelerate the generation of best actionable evidence and expertise on vaccine coverage, benefits and risks.
The overall mission of VAC4EU is to enable, coordinate and accelerate the generation of best actionable evidence and expertise on vaccine coverage, benefits and risks.
The four members of the Executive Board lead by Miriam Sturkenboom represent this non-profit international association integrated at present by 24 members. Amongst other key assignments, this decision-making body outlines the annual plan of activities and the long-term strategic vision of VAC4EU. It is also responsible for the implementation of its policies and annual plan, once it has the approval of the General Assembly.
This decision-making body outlines the annual plan of activities and the long-term strategic vision of VAC4EU and is responsible of their implementation.
Besides having the right to perform administrative acts, the Executive Board can also request strategic and scientific advice to independent groups, approve and amend bylaws, appoint the Secretary-General and approve standards and procedures for conducting studies under the VAC4EU label. This executive body also provides recommendations to the General Assembly on applications for Membership and is responsible for the overall financial management of the organisation.
VAC4EU is the successor of the ADVANCE project, a public private partnership which was funded by the Innovative Medicines Initiative from 2013 to 2019. Research and public health organizations can join VAC4EU.
As part of Teamit Research, Teamit Institute focuses on the scientific management of multinational drug safety and pharmacoepidemiology research.
More information about Teamit Institute here.
More information about VAC4EU here.
